Viking Therapeutics (VKTX) Expected to Announce Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is projected to release its Q3 2025 results after the market closes on Wednesday, October 22nd. Analysts expect Viking Therapeutics to post earnings of ($0.71) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, October 22, 2025 at 4:30 PM ET.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.14). During the same quarter in the previous year, the firm earned ($0.20) EPS. The firm’s revenue for the quarter was up NaN% on a year-over-year basis. On average, analysts expect Viking Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Viking Therapeutics Stock Down 3.5%

NASDAQ VKTX opened at $33.53 on Monday. Viking Therapeutics has a 52-week low of $18.92 and a 52-week high of $81.73. The business’s 50-day moving average price is $29.23 and its 200 day moving average price is $28.42. The firm has a market cap of $3.77 billion, a P/E ratio of -21.92 and a beta of 0.64.

Analyst Ratings Changes

A number of equities analysts recently issued reports on VKTX shares. HC Wainwright reissued a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a report on Monday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Viking Therapeutics in a report on Wednesday, October 8th. BTIG Research reissued a “buy” rating and set a $125.00 price target on shares of Viking Therapeutics in a report on Monday, September 22nd. Raymond James Financial cut their price target on shares of Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating for the company in a report on Thursday, July 24th. Finally, Citigroup increased their price target on shares of Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Viking Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $86.42.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. grew its position in Viking Therapeutics by 29.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,109 shares of the biotechnology company’s stock worth $56,000 after buying an additional 481 shares during the period. Tower Research Capital LLC TRC grew its position in Viking Therapeutics by 307.6% during the second quarter. Tower Research Capital LLC TRC now owns 6,974 shares of the biotechnology company’s stock worth $185,000 after buying an additional 5,263 shares during the period. Prudential Financial Inc. acquired a new position in Viking Therapeutics during the second quarter worth about $196,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Viking Therapeutics in the second quarter valued at approximately $239,000. Finally, Tidal Investments LLC acquired a new stake in shares of Viking Therapeutics in the second quarter valued at approximately $251,000. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.